CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study

The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis


(2018) Kai Liao et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Relevance of CYP2C9 Function in Valproate Therapy

(2018) Katalin Monostory et al.   Current Neuropharmacology

Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology

(2017) Robert S. Fisher et al.   EPILEPSIA

ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology

(2017) Ingrid E. Scheffer et al.   EPILEPSIA

The role of genetic testing in epilepsy diagnosis and management

(2017) Yvonne G. Weber et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Influence of genetic variants of CYP2D6 , CYP2C9 , CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy

(2017) Miguel A. López-García et al.   Pharmacological Reports

CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes andphenytoin adverse reactions correlation

(2017) Carlos Alexandre Twardowschy et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy

(2016) Nagendra Chaudhary et al.   BMC Pediatrics

Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance

(2015) Shazia Kousar et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

(2015) A Ortega-Vázquez et al.   PHARMACOGENOMICS JOURNAL

Les critères prédictifs d’une épilepsie pharmacorésistante chez l’enfant

(2015) S. Fray et al.   REVUE NEUROLOGIQUE

Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs

(2014) NJ Gogtay et al.   Journal of Postgraduate Medicine

The Effect of Genetic Polymorphisms of Cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on Drug-Resistant Epilepsy in Turkish Children

(2013) Mehmet Seven et al.   Molecular Diagnosis & Therapy

CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database

(2013) D-P Dai et al.   PHARMACOGENOMICS JOURNAL

Prevalence of CYP2C19 polymorphisms in the Lebanese population

(2011) Isabelle Djaffar Jureidini et al.   MOLECULAR BIOLOGY REPORTS

Predictors of refractory epilepsy in North India: A case–control study

(2011) Manjari Tripathi et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients

(2010) Ramasamy Kesavan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Genetic factors associated with drug-resistance of epilepsy: Relevance of stratification by patient age and aetiology of epilepsy

(2010) M. Blanca Sánchez et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Drug interactions involving the new second- and third-generation antiepileptic drugs

(2009) Cecilie Johannessen Landmark et al.   Expert Review of Neurotherapeutics

Early prediction of refractory epilepsy in childhood

(2009) J. Ramos-Lizana et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Newly diagnosed single unprovoked seizures and epilepsy in Stockholm, Sweden: First report from the Stockholm Incidence Registry of Epilepsy (SIRE)

(2008) Cecilia Adelöw et al.   EPILEPSIA